ELN441958: bradykinin B1 Receptor antagonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11848206 |
| CHEMBL ID | 1254945 |
| SCHEMBL ID | 1712902 |
| MeSH ID | M0513560 |
| Synonym |
|---|
| bdbm50326710 |
| CHEMBL1254945 , |
| 7-chloro-2-(3-(9-(pyridin-4-yl)-3,9-diazaspiro[5.5]undecane-3-carbonyl)phenyl)isoindolin-1-one |
| eln-441958 |
| 1h-isoindol-1-one, 7-chloro-2,3-dihydro-2-(3-((9-(4-pyridinyl)-3,9-diazaspiro(5.5)undec-3-yl)carbonyl)phenyl)- |
| g62x909y89 , |
| 7-chloro-2-(3-((9-(pyridin-4-yl)-3,9-diazaspiro(5.5)undecan-3-yl)carbonyl)phenyl)-2,3-dihydroisoindol-1-one |
| 3,9-diazaspiro(5.5)undecane, 3-(3-(7-chloro-1,3-dihydro-1-oxo-2h-isoindol-2-yl)benzoyl)-9-(4-pyridinyl)- |
| unii-g62x909y89 |
| 913064-47-8 |
| 7-chloro-2-[3-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undecane-3-carbonyl)-phenyl]-2,3-dihydro-isoindol-1-one |
| ARYQHSWJGHCGJS-UHFFFAOYSA-N , |
| CS-4807 |
| SCHEMBL1712902 |
| AKOS025293444 |
| HY-15043 |
| eln441958 |
| eln 441958 |
| 7-chloro-2-{3-[9-(pyridin-4-yl)-3,9-diazaspiro[5.5]undecane-3-carbonyl]phenyl}-2,3-dihydro-1h-isoindol-1-one |
| NCGC00485481-01 |
| 7-chloro-2-(3-(9-pyridin-4-yl-3,9-diaza-spiro[5.5]undecane-3-carbonyl)phenyl)-2,3-dihydroisoindol-1-one |
| FT-0762514 |
| eln441958; eln-441958 |
| BCP23812 |
| EX-A2054 |
| Q27278818 |
| 7-chloro-2-[3-(9-pyridin-4-yl-3,9-diazaspiro[5.5]undecane-3-carbonyl)phenyl]-3h-isoindol-1-one |
| A916899 |
| BS-51612 |
| E85203 |
| AC-35915 |
ELN441958 is a novel small molecule bradykinin B(1) receptor antagonist exhibiting high oral bioavailability and potent systemic efficacy in rhesus monkey inflammatory pain.
| Excerpt | Reference | Relevance |
|---|---|---|
| "ELN441958 is a novel small molecule bradykinin B(1) receptor antagonist exhibiting high oral bioavailability and potent systemic efficacy in rhesus monkey inflammatory pain." | ( Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. Bova, MP; Butelman, ER; Chavez, RA; Chen, L; Dreyer, M; Fukuda, JY; Garofalo, AW; Hawkinson, JE; Holcomb, R; Hom, DS; Ko, MC; Liao, A; Malmberg, AB; Ruslim, L; Samant, B; Simmonds, S; Szoke, BG; Wadsworth, A; Zeitz, KP; Zhang, H; Zmolek, W, 2007) | 1.27 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 26.2123 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 26.2123 | 0.0033 | 9.1582 | 39.8107 | AID1347411 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| B1 bradykinin receptor | Homo sapiens (human) | Ki | 0.0003 | 0.0002 | 0.0957 | 0.3820 | AID514938 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytokine activity | Interferon beta | Homo sapiens (human) |
| cytokine receptor binding | Interferon beta | Homo sapiens (human) |
| type I interferon receptor binding | Interferon beta | Homo sapiens (human) |
| protein binding | Interferon beta | Homo sapiens (human) |
| chloramphenicol O-acetyltransferase activity | Interferon beta | Homo sapiens (human) |
| bradykinin receptor activity | B1 bradykinin receptor | Homo sapiens (human) |
| protein binding | B1 bradykinin receptor | Homo sapiens (human) |
| peptide binding | B1 bradykinin receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular space | Interferon beta | Homo sapiens (human) |
| extracellular region | Interferon beta | Homo sapiens (human) |
| endoplasmic reticulum | B1 bradykinin receptor | Homo sapiens (human) |
| plasma membrane | B1 bradykinin receptor | Homo sapiens (human) |
| plasma membrane | B1 bradykinin receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID513672 | Clearance in monkey at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. |
| AID513673 | Antihyperalgesic activity against carrageenan-induced thermal hyperalgesia in rhesus monkey assessed as tail withdrawal latency | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. |
| AID514951 | Oral bioavailability in Sprague-Dawley rat at 10 mg/kg | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. |
| AID513671 | Half life in monkey at 1 mg/kg, iv | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. |
| AID514954 | Half life in Sprague-Dawley rat at 2.5 mg/kg, iv | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. |
| AID514955 | Clearance in Sprague-Dawley rat at 2.5 mg/kg, iv | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. |
| AID514938 | Displacement of [3H]Lys0-des-Arg9-BK at human bradykinin B1 receptor expressed in HEK293 cells | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. |
| AID513670 | Oral bioavailability in monkey at 5 mg/kg | 2010 | Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15 | Bradykinin B1 receptor antagonists as potential therapeutic agents for pain. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.79) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||